Skip to content
Review

WEIGHT LOSS DIETS and MACRONUTRIENT INTAKE IN MASLD: A CROSS-SECTIONAL ANALYSIS OF THE U.S. POPULATION.

Sep 2026 · American Journal of the Medical Sciences · 0 citations · 14 references
Medicine

Abstract

Background

Key dietary patterns targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) generally emphasize caloric restriction. However, dietary differences between individuals with and without MASLD remain unclear. This population-based cross-sectional study compares self-reported dietary patterns between individuals with and without MASLD in the US.

Methods

We analyzed 2017-2018 National Health and Nutrition Examination Survey (NHANES) data on adults (≥18) with and without MASLD. Self-reported low-calorie diets versus no specific diet were examined. Dietary intake was assessed via 24-hour recalls.

Results

The NHANES survey included 5856 adults, 1566 (26.7%) of whom met criteria for MASLD. Among MASLD participants, 11.2% (175/1566) reported following a low-calorie diet compared to 7.5% (180/2401) of non-MASLD controls (p < 0.001). Within the low-calorie group, MASLD participants reported higher caloric intake than controls (2,159 vs. 1,883 kcals; p = 0.004), carbohydrates (242 vs. 205g; p < 0.001), and fat (90 vs. 76g; p = 0.04). Among all adults with MASLD, caloric intake did not differ by diet status (low calorie dieters vs non-dieters) (2205 vs. 2159 kcals; p = 0.545) although the non-dieters consumed more sugar (114 vs. 93g; p = 0.01) and the diet group consumed more sodium (3897 vs 3587 mg/d; p=0.03).

Conclusion

Among participants reporting low-calorie diets, MASLD participants consumed more calories, particularly from fats and carbohydrates, than non-MASLD controls. Nutrient profiles were similar regardless of dieting status in MASLD participants. These findings suggest that self-reported dietary adherence may not always reflect actual dietary intake. Given the central role of diet in MASLD outcomes, inconsistencies in dietary composition may partially explain variability in placebo responses observed in clinical trials. These findings need further confirmation to inform improvements in trial designs and intervention strategies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.